Expert committees and study groups

Appointments to expert advisory panels and committees

Report by the Secretariat\(^1\)

ESTABLISHMENT OR DISESTABLISHMENT OF EXPERT ADVISORY PANELS

1. The WHO Expert Advisory Panel on Tobacco or Health was disestablished. A new study group with a focus on tobacco product regulation has been established.

MEMBERSHIP OF THE EXPERT ADVISORY PANELS

2. Membership of the 54 expert advisory panels totalled 1064 in December 2003, compared with 1185 in December 2002. Of the regional distribution of all members of all panels, 9% come from the African Region, 24% from the Region of the Americas, 10% from the South-East Asia Region, 35% from the European Region, 9% from the Eastern Mediterranean Region and 13% from the Western Pacific Region. Of the total of all members of all panels, 20% are women.

3. Attached is a list of all panels, which includes a breakdown of members by panel, region and sex, as of December 2003. Further details (alphabetical list of experts giving nationality) can be made available should members of the Board so request.

MEETINGS OF EXPERT COMMITTEES

4. The following committees met in 2003:

   - Advisory Committee on Health Research (41st Session), Geneva, 10-12 June (14 WHO members: 11 men, three women)

   - Expert Committee on Biological Standardization, Geneva, 17-21 February (10 WHO members: seven men, three women); 17-21 November (nine WHO members: seven men, two women)

\(^1\)This report is submitted to the Executive Board in compliance with regulation 4.23 of the Regulations for Expert Advisory Panels and Committees.
Expert Committee on Specifications for Pharmaceutical Preparations, Geneva, 10-14 March (10 members: seven men, three women)

Expert Committee on the Selection and Use of Essential Medicines, Geneva, 31 March – 3 April (nine members: six men, three women)

Joint FAO/WHO Expert Committee on Food Additives (60th Session), Geneva, 6-12 February (five WHO members: five men); (61st Session), Rome, 10-19 June (six WHO members: five men, one woman).

5. Invitations to take part in these meetings were extended to 63 panel members from 30 different countries, drawn from 13 expert advisory panels (four members were unable to attend).

6. Following the amendments to the regulations for expert advisory panels and committees introduced by resolution WHA55.24, Regional Directors have been requested to assist the Director-General in nominating experts from developing countries in a more representative and comprehensive manner. Guidance on such assistance was noted by the Fifty-sixth World Health Assembly.¹

¹ Documents A56/41 and WHA56/2003/REC/3, summary record of the fourth meeting of Committee B.
### MEMBERSHIP OF WHO EXPERT ADVISORY PANELS BY PANEL AND REGION

<table>
<thead>
<tr>
<th>WHO expert advisory panels</th>
<th>Africa</th>
<th>Americas</th>
<th>South-East Asia</th>
<th>Europe</th>
<th>Eastern Mediterranean</th>
<th>Western Pacific</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute bacterial diseases</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>8</td>
<td>2</td>
<td>1</td>
<td>17</td>
</tr>
<tr>
<td>Acute diarrhoeal diseases and other enteric infections</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Ageing and health</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>21</td>
</tr>
<tr>
<td>Biological standardization</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>34</td>
</tr>
<tr>
<td>Blood transfusion medicine</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>23</td>
</tr>
<tr>
<td>Brucellosis</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Cancer</td>
<td>1</td>
<td>0</td>
<td>11</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>32</td>
</tr>
<tr>
<td>Cardiovascular diseases</td>
<td>3</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Chronic degenerative diseases (diabetes)</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Chronic degenerative diseases (rheumatic diseases)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Clinical surgical procedures</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Development of human resources for health</td>
<td>5</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>5</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Drug dependence (dependence liability evaluation)</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Drug dependence and alcohol problems</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Drug evaluation</td>
<td>4</td>
<td>1</td>
<td>6</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Drug policies and management</td>
<td>6</td>
<td>2</td>
<td>5</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Food safety</td>
<td>4</td>
<td>0</td>
<td>17</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Health laboratory services</td>
<td>2</td>
<td>0</td>
<td>7</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Health promotion and education</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Health science and technology policy</td>
<td>4</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Health situation and trend assessment</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Human genetics</td>
<td>2</td>
<td>0</td>
<td>7</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Human reproduction</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Immunology</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Injury and violence prevention and control</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>International pharmacopoeia and pharmaceutical preparations</td>
<td>8</td>
<td>0</td>
<td>11</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>Leprosy</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Malaria</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>14</td>
</tr>
</tbody>
</table>

| Total%                                                                                     | 17 3   | 7 29  | 21 38  | 34 15  | 23 39  | 1 0  | 32 6  |

Numbers of panel members, as of December 2003
<table>
<thead>
<tr>
<th>WHO expert advisory panels</th>
<th>Africa</th>
<th>The Americas</th>
<th>South-East Asia</th>
<th>Europe</th>
<th>Eastern Mediterranean</th>
<th>Western Pacific</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>W</td>
<td>N</td>
<td>W</td>
<td>N</td>
<td>W</td>
<td>N</td>
</tr>
<tr>
<td>Maternal and child health</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Mental health</td>
<td>1</td>
<td>0</td>
<td>11</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td>Neurosciences</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Nursing</td>
<td>5</td>
<td>4</td>
<td>9</td>
<td>9</td>
<td>5</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Nutrition</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Oral health</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Organization of medical care</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Parasitic diseases (filarial infections)</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Parasitic diseases (general parasitology)</td>
<td>4</td>
<td>0</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>Parasitic diseases (leishmaniasis)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Parasitic diseases (schistosomiasis)</td>
<td>2</td>
<td>0</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Parasitic diseases (trypanosomiasis)</td>
<td>2</td>
<td>0</td>
<td>12</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Prevention of blindness</td>
<td>2</td>
<td>1</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Prevention of deafness and hearing impairment</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Public health administration</td>
<td>1</td>
<td>0</td>
<td>5</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Rabies</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Radiation</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Rehabilitation</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory infections</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Sexually transmitted infections including those due to human immunodeficiency virus</td>
<td>2</td>
<td>0</td>
<td>6</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Traditional medicine</td>
<td>3</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>4</td>
<td>2</td>
<td>7</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Vector biology and control</td>
<td>2</td>
<td>0</td>
<td>10</td>
<td>0</td>
<td>5</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td>Virus diseases</td>
<td>1</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Virus diseases (antivirals and interferon)</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Zoonoses</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>4</td>
</tr>
</tbody>
</table>

Total | 94 | 19 | 255 | 60 | 107 | 30 | 369 | 57 | 96 | 19 | 143 | 27 | 1064 | 212 | 20 |

N: total number of panel members; W: number of women members; %: percentage of total number of panel members who are women.